Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Repurchased

Daily Values

Growth Metrics

Surgery Partners (SGRY) Shares Issued (2021 - 2022)

Surgery Partners (SGRY) has disclosed Shares Issued for 2 consecutive years, with $882.9 million as the latest value for Q4 2022.

Quarterly Shares Issued rose 175.13% to $882.9 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $882.9 million through Dec 2022, up 51.75% year-over-year, with the annual reading at $882.9 million for FY2022, 51.75% up from the prior year.
Shares Issued hit $882.9 million in Q4 2022 for Surgery Partners, up from $320.9 million in the prior quarter.
In the past five years, Shares Issued ranged from a high of $882.9 million in Q4 2022 to a low of -$0.0 in Q3 2021.